Colorectal Cancer Screening Market to Hit USD 27.83 Billion by 2032, Driven by Rising Preventive Health Awareness and Technological Advancements – SNS Insider
According to Research by SNS Insider, U.S. Colorectal Cancer Screening Market to Reach USD 9.54 Billion by 2032, Driven by Increasing Early Detection Efforts and Screening Compliance.
Austin, July 21, 2025 (GLOBE NEWSWIRE) — Colorectal Cancer Screening Market Size & Growth Analysis:
According to SNS Insider, the global Colorectal Cancer Screening Market was valued at USD 15.36 billion in 2023 and is projected to grow to USD 27.83 billion by 2032, registering a CAGR of 6.85% during the forecast period of 2024-2032.
Rising Incidence and Emphasis on Early Detection Fuel Growth
The market is experiencing significant growth, driven by increasing government-backed screening programs, public health campaigns, and a shift toward non-invasive, patient-preferred testing methods. Advances in diagnostic technologies and AI-powered tools are also transforming the landscape, improving accuracy and compliance rates among patients.
Request Your Free Sample Copy of the Colorectal Cancer Screening Market Report Today: https://www.snsinsider.com/sample-request/4950
Market Overview
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide, and early detection significantly increases survival rates. The global colorectal cancer screening market is experiencing robust growth due to rising awareness campaigns, growing demand for early diagnostic solutions, and widespread adoption of non-invasive screening alternatives. The market’s rapid evolution is supported by strong governmental and healthcare organizational initiatives promoting regular screening, especially among individuals aged 45 and above.
In the U.S., which accounted for USD 5.41 billion in 2023, rising health expenditure, advanced infrastructure, and higher compliance rates have made it a key contributor to global market expansion. The country is expected to reach USD 9.54 billion by 2032, benefiting from strong reimbursement policies and increasing uptake of blood-based and stool DNA testing. Moreover, AI-powered tools and next-gen biomarkers are significantly improving detection accuracy, helping to drive early intervention and reduce mortality.
Major Players Analysis Listed in this Report are:
- Exact Sciences Corporation (Cologuard, Oncotype DX Colon Cancer Assay)
- Abbott Laboratories (RealTime IDH1 Assay, mS9 Biomarker Screening Test)
- Qiagen (Therascreen KRAS RGQ PCR Kit, PreAnalytiX PAXgene Stool Kit)
- Roche Diagnostics (Elecsys CEA Assay, Cobas EGFR Mutation Test)
- Sysmex Corporation (HISCL Tumor Marker Test, Colon Cancer Screening FOBT)
- Eiken Chemical Co., Ltd. (OC-Sensor FIT System, LAMP DNA Amplification Test)
- Fujirebio Diagnostics (Lumipulse G CEA, Lumipulse G FOB Plus)
- Thermo Fisher Scientific (Oncomine Dx Target Test, QuantStudio Dx Real-Time PCR System)
- Hologic, Inc. (Aptima KRAS Mutation Assay, Panther Fusion Assay)
- Bio-Techne Corporation (ACD RNAscope Assay, Tumor Microenvironment Panel)
- Guardant Health (Guardant360 Liquid Biopsy, Reveal Test for Minimal Residual Disease)
- Natera, Inc. (Signatera, Prospera Transplant Assessment Test)
- Siemens Healthineers (ADVIA Centaur CEA Assay, Atellica IM Tumor Marker Assay)
- Invitae Corporation (Comprehensive Hereditary Cancer Panel, Genetic Risk Assessment for Colon Cancer)
- PerkinElmer Inc. (LabChip GX Touch Nucleic Acid Analyzer, GSP Neonatal Screening Platform)
- Epigenomics AG (Epi proColon, Epi proLung BL Reflex Assay)
- Beckman Coulter, Inc. (Access CEA Tumor Marker Test, DxH 900 Hematology Analyzer)
- Becton, Dickinson and Company (BD MAX Molecular Diagnostics System, FIT Hemoccult Test)
- Illumina, Inc. (TruSight Oncology 500, NovaSeq Sequencing Platform)
- Myriad Genetics, Inc. (myRisk Hereditary Cancer Test, myChoice CDx for Genetic Testing)
Colorectal Cancer Screening Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 15.36 billion |
| Market Size by 2032 | US$ 27.83 billion |
| CAGR | CAGR of 6.85% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Regional Analysis | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Key Growth Drivers | The increasing prevalence of colorectal cancer globally is a major driver of growth in the Colorectal Cancer Screening Market. |
Segment Analysis
By Type:
In 2023, colonoscopy was the largest segment with a share of 50% owing to its ability to provide a complete diagnosis and act as a well-established gold standard in CRC screening. It allows for both detection and removal of polyps during one procedure, which would enhance its clinical applicability. The stool-based tests market, however, is the fastest growing market due to the increasing patient preference for non-invasive and home-based test formats and the rise in development of multi-target DNA test kits.
By End-User:
Hospitals & clinics dominated the market in 2023 on account of easy access, professional experts, and insurance coverage, leading to the effective utilization for screening, diagnosis, and follow-ups. In contrast, the diagnostic laboratories segment is expected to register the fastest growth, backed by a rise in collaborations and agreements with at-home test kit manufacturers, an enhancement in sample analysis techniques, and a rise in adoption of high-throughput molecular testing platforms.
For a Personalized Briefing with Our Industry Analysts, Connect Now: https://www.snsinsider.com/request-analyst/4950
Colorectal Cancer Screening Market Segmentation
By Type
- Stool based
- Fecal immunological test (FTI)
- Fecal occult blood test (FOBT)
- Stool DNA test
- Colonoscopy
- Others
By End-User
- Hospitals & clinics
- Clinical laboratories
- Diagnostic Imaging Centers
- Others
Regional Analysis
Based on geography, in 2023 North America dominated the world colorectal cancer screening industry accounting for over 40% share owing to well-established awareness, superior healthcare infrastructure and higher spending in diagnostics. Powerhouse players that include Exact Sciences, Quest Diagnostics and Roche Diagnostics have also helped drive innovation and access in the region.
Asia Pacific is expected to be the fastest-growing region in the forecast period. Growing prevalence rate, developing healthcare infrastructure, and rising government expenditure on cancer preventive programs are some other factors propelling the market. Indigenous countries, such as those I work in (China, India) are rapidly integrating stool-based screening and immunochemical fecal testing into national healthcare systems.
Recent Developments
- September 2024 – Exact Sciences developed the most advanced blood-based test for detecting colorectal cancer. Citing their proprietary scientific approach and the development of an innovative marker panel that had led to superior screening accuracy and the possibility of earlier detection.
- November 2024 – Qiagen has incorporated another dimension to its presence in the colorectal cancer diagnostics market non-invasive solutions upgrades. The company noted it leads in stool-based DNA testing and liquid biopsy testing and has driven early cancer detection programmes in countries around the world.
- October 2024 – Roche Diagnostics released MSIntuit CRC v2, in partnership with AI firm Owkin. Built into the Navify Digital Pathology suite, the AI-based diagnostic solution can improve analysis of biopsies and resections, supporting improved treatment planning and personalized medicine.
Buy the Full Colorectal Cancer Screening Market Report (Single-User License) Now: https://www.snsinsider.com/checkout/4950
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
5.1 Screening Uptake Trends (2023)
5.2 Shift Towards Non-Invasive Methods:(2023)
5.3 Rising Colorectal Cancer Incidence (2020-2032)
5.4 Colonoscopy’s Continued Relevance (2023)
5.5 Economic Impact (2023)
6. Competitive Landscape
7. Colorectal Cancer Screening Market by Type
8. Colorectal Cancer Screening Market by End User
9. Regional Analysis
10. Company Profiles
11. Use Cases and Best Practices
12. Conclusion
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.
